Market closed
MeiraGTx/$MGTX
MeiraGTx shares are trading higher after the company reported Q1 results and announced a strategic collaboration with Hologen AI, including a $200 million upfront payment and a joint venture for Parkinson's disease development.
11 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
372
ISIN
KYG596651029
Website
MeiraGTx Metrics
BasicAdvanced
$405M
-
-$2.27
1.31
-
Price and volume
Market cap
$405M
Beta
1.31
52-week high
$8.75
52-week low
$3.85
Average daily volume
677K
Financial strength
Current ratio
1.525
Quick ratio
1.37
Long term debt to equity
234.391
Total debt to equity
244.352
Interest coverage (TTM)
-12.17%
Management effectiveness
Return on assets (TTM)
-37.28%
Return on equity (TTM)
-216.14%
Valuation
Price to revenue (TTM)
10.744
Price to book
12.09
Price to tangible book (TTM)
12.38
Price to free cash flow (TTM)
-3.384
Growth
Revenue change (TTM)
203.23%
Earnings per share change (TTM)
84.70%
3-year revenue growth (CAGR)
-3.78%
3-year earnings per share growth (CAGR)
5.00%
What the Analysts think about MeiraGTx
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
MeiraGTx Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MeiraGTx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MeiraGTx News
AllArticlesVideos
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewsWire·2 days ago
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
GlobeNewsWire·3 days ago
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease
GlobeNewsWire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $405M as of May 16, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of May 16, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.